PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...

CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...

The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...

PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...

Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...

Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...

AnnJi Pharmaceutical has filed its Phase 3 protocol with the FDA and is moving to activate U.S. sites for ROMA-KD, a global, randomized, double-blind, placebo-controlled trial targeting roughly 200 ...

Influenza killed at least 24,000 Americans during the 2025–2026 season despite widespread vaccination, and that gap is precisely where ArkBio is planting its flag. The Shanghai-based company cleared ...

Vanda Pharmaceuticals’ Phase III trial of VQW-765 in social anxiety disorder failed its primary endpoint with a margin so thin it barely registers: female participants who received the drug scored ...

Eight patients into a first-in-human trial, and no dose-limiting toxicities have appeared. That number is small, but for a radiopharmaceutical targeting CD44v6-positive solid tumors in patients who ...

FT2109 cleared its Phase 1 trial with once-daily oral dosing, dose-proportional pharmacokinetics, and a safety profile that Forward Therapeutics says supports moving directly into Phase 2, skipping ...

Three years out from enrollment, roughly twice as many patients treated with enfortumab vedotin plus pembrolizumab were alive compared with those who received platinum-based chemotherapy in the EV-302 ...